Dyve Biosciences, Inc.

Quick facts

Phase 2 pipeline

• DYV700 · Oncology
  DYV700 is a small molecule inhibitor of the CDK9 enzyme.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Dyve Biosciences, Inc. portfolio CI brief
• Dyve Biosciences, Inc. pipeline updates RSS